Cargando…
Machine learning based personalized drug response prediction for lung cancer patients
Lung cancers with a mutated epidermal growth factor receptor (EGFR) are a major contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been developed against EGFR and show encouraging results for survival rate and quality of life. However, drug resistance may affe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640729/ https://www.ncbi.nlm.nih.gov/pubmed/36344580 http://dx.doi.org/10.1038/s41598-022-23649-0 |
_version_ | 1784825925079138304 |
---|---|
author | Qureshi, Rizwan Basit, Syed Abdullah Shamsi, Jawwad A. Fan, Xinqi Nawaz, Mehmood Yan, Hong Alam, Tanvir |
author_facet | Qureshi, Rizwan Basit, Syed Abdullah Shamsi, Jawwad A. Fan, Xinqi Nawaz, Mehmood Yan, Hong Alam, Tanvir |
author_sort | Qureshi, Rizwan |
collection | PubMed |
description | Lung cancers with a mutated epidermal growth factor receptor (EGFR) are a major contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been developed against EGFR and show encouraging results for survival rate and quality of life. However, drug resistance may affect treatment plans and treatment efficacy may be lost after about a year. Predicting the response to EGFR-TKIs for EGFR-mutated lung cancer patients is a key research area. In this study, we propose a personalized drug response prediction model (PDRP), based on molecular dynamics simulations and machine learning, to predict the response of first generation FDA-approved small molecule EGFR-TKIs, Gefitinib/Erlotinib, in lung cancer patients. The patient’s mutation status is taken into consideration in molecular dynamics (MD) simulation. Each patient’s unique mutation status was modeled considering MD simulation to extract molecular-level geometric features. Moreover, additional clinical features were incorporated into machine learning model for drug response prediction. The complete feature set includes demographic and clinical information (DCI), geometrical properties of the drug-target binding site, and the binding free energy of the drug-target complex from the MD simulation. PDRP incorporates an XGBoost classifier, which achieves state-of-the-art performance with 97.5% accuracy, 93% recall, 96.5% precision, and 94% F1-score, for a 4-class drug response prediction task. We found that modeling the geometry of the binding pocket combined with binding free energy is a good predictor for drug response. However, we observed that clinical information had a little impact on the performance of the model. The proposed model could be tested on other types of cancers. We believe PDRP will support the planning of effective treatment regimes based on clinical-genomic information. The source code and related files are available on GitHub at: https://github.com/rizwanqureshi123/PDRP/. |
format | Online Article Text |
id | pubmed-9640729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96407292022-11-15 Machine learning based personalized drug response prediction for lung cancer patients Qureshi, Rizwan Basit, Syed Abdullah Shamsi, Jawwad A. Fan, Xinqi Nawaz, Mehmood Yan, Hong Alam, Tanvir Sci Rep Article Lung cancers with a mutated epidermal growth factor receptor (EGFR) are a major contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been developed against EGFR and show encouraging results for survival rate and quality of life. However, drug resistance may affect treatment plans and treatment efficacy may be lost after about a year. Predicting the response to EGFR-TKIs for EGFR-mutated lung cancer patients is a key research area. In this study, we propose a personalized drug response prediction model (PDRP), based on molecular dynamics simulations and machine learning, to predict the response of first generation FDA-approved small molecule EGFR-TKIs, Gefitinib/Erlotinib, in lung cancer patients. The patient’s mutation status is taken into consideration in molecular dynamics (MD) simulation. Each patient’s unique mutation status was modeled considering MD simulation to extract molecular-level geometric features. Moreover, additional clinical features were incorporated into machine learning model for drug response prediction. The complete feature set includes demographic and clinical information (DCI), geometrical properties of the drug-target binding site, and the binding free energy of the drug-target complex from the MD simulation. PDRP incorporates an XGBoost classifier, which achieves state-of-the-art performance with 97.5% accuracy, 93% recall, 96.5% precision, and 94% F1-score, for a 4-class drug response prediction task. We found that modeling the geometry of the binding pocket combined with binding free energy is a good predictor for drug response. However, we observed that clinical information had a little impact on the performance of the model. The proposed model could be tested on other types of cancers. We believe PDRP will support the planning of effective treatment regimes based on clinical-genomic information. The source code and related files are available on GitHub at: https://github.com/rizwanqureshi123/PDRP/. Nature Publishing Group UK 2022-11-07 /pmc/articles/PMC9640729/ /pubmed/36344580 http://dx.doi.org/10.1038/s41598-022-23649-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Qureshi, Rizwan Basit, Syed Abdullah Shamsi, Jawwad A. Fan, Xinqi Nawaz, Mehmood Yan, Hong Alam, Tanvir Machine learning based personalized drug response prediction for lung cancer patients |
title | Machine learning based personalized drug response prediction for lung cancer patients |
title_full | Machine learning based personalized drug response prediction for lung cancer patients |
title_fullStr | Machine learning based personalized drug response prediction for lung cancer patients |
title_full_unstemmed | Machine learning based personalized drug response prediction for lung cancer patients |
title_short | Machine learning based personalized drug response prediction for lung cancer patients |
title_sort | machine learning based personalized drug response prediction for lung cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640729/ https://www.ncbi.nlm.nih.gov/pubmed/36344580 http://dx.doi.org/10.1038/s41598-022-23649-0 |
work_keys_str_mv | AT qureshirizwan machinelearningbasedpersonalizeddrugresponsepredictionforlungcancerpatients AT basitsyedabdullah machinelearningbasedpersonalizeddrugresponsepredictionforlungcancerpatients AT shamsijawwada machinelearningbasedpersonalizeddrugresponsepredictionforlungcancerpatients AT fanxinqi machinelearningbasedpersonalizeddrugresponsepredictionforlungcancerpatients AT nawazmehmood machinelearningbasedpersonalizeddrugresponsepredictionforlungcancerpatients AT yanhong machinelearningbasedpersonalizeddrugresponsepredictionforlungcancerpatients AT alamtanvir machinelearningbasedpersonalizeddrugresponsepredictionforlungcancerpatients |